Institute of Isotopes Co., Ltd. Products Technical Support Search Sitemap Contact
INSTITUTE OF ISOTOPES CO., LTD. Free triiodothyronine (FT3) RIA kit (RK-33CT) - coated tube
COMPANY
About Us
Contact

BUSINESS UNITS
Radiopharmaceutical
Immunoassay
Molecular Biology
Synthesis
Radiation Technique

PRODUCTS
Complete List
New Products
Technical Support

QUOTATION REQUEST

SEARCH
|| Sitemap

*** Magyar ***

Description

The FT3 [125I] RIA system provides a quantitative in vitro determination of free triiodothyronine (FT3) in human serum in the range 0-40 pmol/l (0-26 pg/ml).

Introduction

Among the thyroid hormones produced in the thyroid gland triiodothyronine (3,5,3'-triiodo-L-thyronine, T3) is regarded as the most biologically active molecule, produced up to 80% by the deiodination of tetraiodothyronine (T4) in pheripheral tissues.

T3 is found in the bloodstream in a major (99.7%) protein-bound, and a minor (0.3%) unbound, fraction. Variations in total thyroid hormone in blood may result from either changes of binding proteins concentrations, or thyroid hormone production. Thyroid disorders are existing only if a net change of free unbound fractions occur persistently, therefore the true measure of thyroid status will be the concentration of free hormones.

Hyperthyroidism is generally associated with an increase of the FT3 concentration, and in some cases the increased FT3 concentration is the only indicator of T3 thyrotoxicosis.

Determination of the free T3 concentration allows also the follow-up of patients under liothyronine therapy.

Principle of method

This assay is based on the competition between FT3 and conjugate (T3 analog bound to biotinylated carrier protein) for a limited number of binding sites on 125I-labelled monoclonal anti-triiodothyronine antibodies (tracer). Allowing to react a fixed amount of conjugate and antibody with different amounts of ligand the radioactivity measured on the solid phase will be inversely proportional to the concentration of ligand. During a 2-hour incubation period with continuous agitation immuno-complex is immobilized on the reactive surface of test tubes. Decanting the supernatant from all tubes the radioactivity in tubes can be measured in a gamma counter.

By plotting binding values against a series of calibrators containing known amount of FT3, a calibration curve is constructed, from which the unknown concentration of FT3 in patient samples can be determined.

Contents of the kit

1 vial 125I-TRACER (55 ml),
containing about 300 kBq 125I-labelled monoclonal antibody in buffer with 0.1% NaN3.
6 vials STANDARDS
0.5 ml per vial, containing 0 (S1), 2 (S2), 5 (S3), 10 (S4), 20 (S5) and 40 (S6) pmol/l FT3 in human serum with 0.1% NaN3
1 vial CONJUGATE (55 ml), ready to use
containing conjugate in buffer with 0.1% NaN3. Do not expose to direct sunlight.
1 vial CONTROL SERUM
Lyophilized human serum with 0.1% NaN3.
The concentration of the control serum is specified in the quality certificate enclosed.
2 boxes COATED TUBE, ready to use.
2 x 50 reactive test tubes, 12x75 mm, packed in plastic boxes.
Quality certificate
Pack leaflet

Materials, tools and equipment required

Test tube rack
Precision pipettes with disposable tips (100 and 500 µl)
Vortex mixer

Shaker
Plastic foil
Absorbent tissue
Gamma counter

Recommended tools and equipment

Repeating pipettes

Preparation of reagents, storage

Tracer, standard and conjugate solutions are ready to use.

Add 500 µl distilled water to the lyophilized control serum. Mix gently with shaking or vortexing (foaming should be avoided).

Ensure that complete dissolution is achieved and allow the solution to equilibrate at room temperature for at least 20 minutes.

Specimen collection and storage

Serum samples can be prepared according to common procedures used routinely in clinical laboratory practice. Samples can be stored at 2-8 °C if the assay is carried out within 24 hours, otherwise aliquots should be prepared and stored deep frozen (-20 °C). Frozen samples should be thawed and thoroughly mixed before assaying. Repeated freezing and thawing should be avoided. Do not use lipemic, hemolyzed or turbid specimens.

Assay procedure

(For a quick guide, refer to Table 1.)

1 Equilibrate reagents and samples to room temperature before use.
2 Label coated tubes in duplicate for total counts (T), zero standard (Standard 1 = B0), standards (S2-6), control (C) and samples (Sx).
3 Homogenize all reagents and samples by gentle mixing to avoid foaming.
4 Pipette 100 µl of each standard, control and sample into the properly labelled tubes.
5 Pipette 500 µl of conjugate into all tubes except T.
6 Pipette 500 µl of tracer solution into all tubes.
7 Fix the test tube rack firmly onto the shaker plate. Turn on the shaker and adjust an adequate speed such that liquid is constantly rotating or shaking in each tube. To ensure efficient rotation, tubes should be firmed tightly inside the test tube rack.
8 Incubate tubes for 2 hours at room temperature.
9 Decant the supernatant from all tubes by the inversion of the rack. In the upside down position place the rack on an absorbent paper for 5 minutes.
10 Count each tube for at least 60 seconds in a gamma counter.
11 Calculate the FT3 concentrations of the samples as described in Calculation of results.

Table 1. Assay Protocol, Pipetting Guide (all volumes in microliters)

 

T

S1-S6

Sx

C

Standard

100

Sample

100

Control

100

Conjugate

500

500

500

Tracer 500 500 500

500

Shake for 2 hours at room temperature.

Decant the fluid and blot on filter paper for 5 minutes.

Count radioactivity (60 sec/tube)

Calculate the results

Calculation of results

The calculation is illustrated using representative data. The assay data collected should be similar to those shown in Table 2.
Calculate the average count per minute (CPM) for each pair of assay tubes.
Calculate the percent B0 / T % for zero standard (S1) by using the following equation:

S1 (cpm)
B0 / T % =  ————   x 100
T (cpm)

Calculate the normalized percent binding for each standard, control and sample respectively by using the following equation:

S2-6 [C, Sx] (cpm)
B / B0 (%) =  ———————   x 100
S1(cpm)

For simplicity, these values are uncorrected for non-specific binding (NSB). This is enabled by low NSB being less than 1.5% of total count.

Using semi-logarithmic graph paper plot B / B0 (%) for each standard versus the corresponding concentration of FT3. Figure 1 shows a typical standard curve.

Determine the FT3 concentration of the unknown samples by interpolation from the standard curve. Do not extrapolate values beyond the standard curve range. Out of fitting programs applied for computerized data processing logit-log, or spline fittings can be used.

Table 2. Typical assay data (Do not use to calculate sample values)

Tubes

Counts CPM1

Counts CPM2

Mean CPM

B/T %

B/B0 %

T

90813

91281

91047

S1

44588

45108

44848

49.3

100.0

S2

39675

39475

39575

43.5

88.2

S3

32476

33349

32913

36.1

73.4

S4

26166

26481

26324

28.9

58.7

S5

18342

18613

18478

20.3

41.2

S6

11419

11142

11281

12.4

25.2

C

35488

35061

35275

38.7

78.7

Characterization of the assay

Typical assay parameters

NSB/T <1%
B0 / T 55 ± 10%
ED-50 11.4 ± 4 pmol/l

Typical standard curve for the FT3 I-125 RIA kit
Figure 1.
Typical standard curve

Conversion of SI units can be performed according to the following formula: 1 pmol/l = 0.0651 ng/dl

Specificity

Four analytes were added in different concentrations to T3 free standard (S1=B0) and the concentration of FT3 was measured.

Analyte added

Conc.
(nmol/l)

FT3
measured (pmol/l)

r-T3

100

<DL

r-T3

1000

3.1

r-T3

10000

28.6

3,3' diiodo-L-thyronine

3

1.3

3,3' diiodo-L-thyronine

10

4.2

3,3' diiodo-L-thyronine

30

16.1

3,5 diiodo-L-thyronine

10

2.1

3,5 diiodo-L-thyronine

30

4.6

3,5 diiodo-L-thyronine

300

38.3

T4

79

<DL

T4

258

1.19

T4

412

3.28

DL – detection limit

Sensitivity

Better than 0.58 pmol/l, corresponding to the 0–2*SD value.

Precision

The within-assay precision was determined with 10 replicates within a single run, the between-assay precision was estimated in 13 independent runs carried out in duplicates (using different shakers, range of temperature during incubation: 20-30 °C), both with 5 samples. CV values are summarized below.

Intra-assay

Inter-assay

Mean (pmol/l)

CV %

Mean (pool/l)

CV %

2.43

9.0

2.71

12.4

3.39

4.6

3.45

7.98

6.44

3.3

6.51

4.76

11.6

3.2

12.9

8.04

40.0

2.2

39.2

5.62

Expected Values

It is recommended that each laboratory establish its own reference intervals. The expected values presented here are based on testing of apparently healthy blood donors. Samples were measured in duplicates. From statistical analysis the following results were obtained.

Age (years)

n

Mean

SD

Min

Max

BL

Female

197

35.4

12.1

18

63

-

Male

200

35.4

11.7

18

64

-

Male+ female

397

35.4

11.9

18

64

-

FT3 (pmol/l)

Female

197

3.35

0.80

1.9

10.2

1.7-5.0

Male

200

3.95

0.63

2.4

6.6

2.7-5.2

Male+ female

397

3.65

0.78

1.9

10.2

2.5-5. 4

BL = Borderline for upper and lower 2.5% from distribution.

As a guide (mean ± 2*SD), 2.09 – 5.21 pmol/l reference range was obtained from normal patients based on statistical considerations only. Taking into consideration not only statistical results but clinical practice as well, a more realistic reference range of 1.9 - 5.7 pmol/l can be recommended.

Additional information

Storage

Store the reagents between 2-8 °C. At this temperature each reagent is stable until expiry date. Control serum should be aliquotted and stored deep frozen (-20 °C) for a repeated use.

Availability

From stock.

Shelf life

The minimum shelf life of kit reagents is usually 8 weeks from the date of manufacturing. The actual expiry date is given on the package label and in the quality certificate. To make the maximum benefit of long-term stability it is recommended to adjust the date of ordering to new-batch manufacturing calendar issued each year. Components from various lots or from kits of different manufacturers should not be mixed or interchanged.

Precaution

Radioactivity

This product contains radioactive material. It is the responsibility of the user to ensure that local regulations or code of practice related to the handling of radioactive materials are satisfied.

Chemical hazard

Components contain sodium azide as an antimicrobial agent. Dispose of waste by flushing with copious amount of water to avoid build-up of explosive metallic azides in copper and lead plumbing. The total azide present in each pack is 113.5 mg.

Biohazard

Human blood products used in the kit have been obtained from healthy human donors. They were tested individually by using approved methods (EIA, enzyme immunoassay), and were found to be negative, for the presence of both Human Immunodeficiency Virus antibody (Anti-HIV-1) and Hepatitis B surface Antigen (HBsAg).

Care should always be taken when handling human specimens to be tested with diagnostic kits. Even if the subject has been tested, no method can offer complete assurance that Hepatitis B Virus, Human Immunodeficiency Virus (HIV-1), or other infectious agents are absent. Human blood samples should therefore be handled as potentially infectious materials.

 

Use by In vitro diagnostic device Control
Batch code Manufacturer Standard
Caution, consult accompanying documents Radioactive material Coated tube
Biological risk Temperature limitation
Store between 2-8 °C
Tracer
Consult instructions for use Catalogue number Conjugate


Other thyroid function assays
Calcitonin IRMA test RK-83M Free T4 RIA test RK-34CT1
Anti-hTG RIA test RK-8CT
TG IRMA test RK-51CT T4 RIA test RK-11M1
Anti-TPO RIA test RK-36CT T4 RIA test RK-11M5
Turbo TSH IRMA test RK-1M1 T4 RIA test RK-11CT1
Turbo TSH IRMA test RK-1M2 T4 RIA test RK-11CT5
Turbo TSH IRMA test RK-1M5 T3 RIA test RK-6M1
Turbo TSH IRMA test RK-1CT1 T3 RIA test RK-6M5
Turbo TSH IRMA test RK-1CT5 T3 RIA test RK-6CT1
Free T4 RIA test RK-34M1 T3 RIA test RK-6CT5
Other immunoassay kits
PRINTABLE VERSION
PDF-FORMAT

Products || Technical Support || Search || Sitemap || Contact || Quotation Request

For business inquiries, please use our Quotation Request form, or check the Contact page.
Your comments about this site (www.izotop.hu) are welcome here: webmaster@izotop.hu